In focus channel feed

Af­ter Roe, star­tups seek to fill Big Phar­ma’s male con­tra­cep­tion gap

10 months ago
Startups

Af­ter abor­tion rul­ing, biotechs be­hind nov­el con­tra­cep­tives say tide is turn­ing on in­sur­ance cov­er­age

10 months ago

DNA se­quenc­ing gi­ant Il­lu­mi­na bat­tles an­titrust reg­u­la­tors and grow­ing com­pe­ti­tion

10 months ago
Pharma

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

11 months ago
Pharma

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

Last year
R&D

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

Last year
People
Discovery

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

Last year
People
AI

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

Last year
People
Discovery

'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this year’s bear mar­ket

Last year
Cell/Gene Tx

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion Warp Speed

Last year

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

Last year
Startups

In­side the race to make psy­che­delics 'main­stream med­i­ci­nes'

Last year
R&D

Ahead of FDA com­mit­tee to dis­cuss new ALS drug, the ju­ry re­mains out on how much ben­e­fit is enough for ap­proval

Last year
R&D
FDA+

Covid vac­cines and drugs are free. But for many im­muno­com­pro­mised pa­tients, pro­tec­tion comes at a cost

Last year
Coronavirus

Bio­phar­ma has hyped AI for years. But as the first tri­als get un­der­way, ex­perts try to man­age ex­pec­ta­tions

Last year
AI

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Last year
Marketing

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

Last year
R&D

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

Last year
Coronavirus

In­side the multi­bil­lion-dol­lar, Sil­i­con Val­ley-backed ef­fort to reimag­ine how the world funds (and con­ducts) sci­ence

Last year
Discovery

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

Last year
R&D
Cell/Gene Tx

EQRx wants to turn drug pric­ing re­form on its head. Can it suc­ceed, or will Big Phar­ma stop it in its tracks?

Last year
Pharma

A new an­ti­body treat­ment of­fers long-await­ed hope for im­muno­com­pro­mised pa­tients, if Omi­cron does­n't get here first

Last year
Coronavirus

Omi­cron is a test for the next pan­dem­ic. Will the world keep mak­ing the same mis­takes?

Last year
Coronavirus

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

Last year
Cell/Gene Tx
First page Previous page 12345 Next page Last page
A service from the Financial Times